2010, On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGR) enzyme.
synthase: participation of invariant acidic residues in formation of the acetyl-S-enzyme reaction intermediate.
The primary goal was to inhibit the enzyme 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGR) responsible for cholesterol biosynthesis in the body.
organic acidurias such as glutaryl-CoA dehydrogenase, 3-hydroxy-3-methylglutaryl-CoA
lyase, [beta]-ketothiolase, Propionyl-CoA carboxylase, Methylmalonyl-CoA mutase, and Isovaleryl-CoA dehydrogenase) (Vreken et al.
reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).
C50H is increased in 3-methylcrotonyl-CoA carboxylase deficiency, 3-hydroxy-3-methylglutaryl-CoA
lyase deficiency, and 3-methylglutaconyl-CoA hydratase deficiency, whereas 2-methyl-3-hydroxybutyrylcarnitine is increased in [beta]-ketothiolase deficiency and 2-methyl-3-hydroxybutyrl-CoA dehydrogenase deficiency (118).
Genes spotted multiple times on different parts of the array include 3-hydroxy-3-methylglutaryl-CoA
reductase, glycosylate reductase, choriogenin 2, a clone that shares homology to Unknown protein (GenBank accession no.
Lyase Deficiency(*)--If this disorder is untreated, it is likely to result in death during childhood.
Partial cloning, tissue distribution and effects of epigallocatechin gallate on hepatic 3-hydroxy-3-methylglutaryl-CoA
reductase mRNA transcripts in goldfish ( Carassius auratus ).
Micro assay for 3-hydroxy-3-methylglutaryl-CoA
reductase in rat liver and in L-cell fibroblasts.
The mRNA expressions of peroxisome proliferator-activated receptor (PPAR) [alpha], diacylglycerol acyltransferase (DGAT), 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase and cholesterol 7[alpha]-hydroxylase (CYP7A) in mouse hepatic tissue or cultured hepatocytes were determined by reverse transcription polymerase chain reaction (RT-PCR).
The combination of fibrates plus 3-hydroxy-3-methylglutaryl-CoA
reductase inhibitors (statins) is an effective and generally well-tolerated treatment for high-risk patients with mixed dyslipidemias, and side effects, mainly hepatic and muscular disorders, are rare.